HOUSTON, TX / ACCESSWIRE / August 10, 2017 / Nexus BioPharma, Inc. (OTC PINK: NEXS), a company specializing in the development of a weight loss drug therapy, announced today the appointment of Robert J. Neborsky, M.D. to the Company's Scientific & Clinical Advisory Board. Robert J. Neborsky, M.D. is a psychiatrist in private practice in Del Mar, California, and a Clinical Professor of Psychiatry at UCSD School of Medicine, as well as UCLA School of Medicine (Hon). He is a Distinguished Life Fellow of the American Psychiatric Association and a founding member on the Editorial Board of the International Journal of Short-Term Dynamic Psychotherapy. He is currently guest editor of the Ad Hoc Bulletin of Short-Term Dynamic Psychotherapy.
Dr. Neborsky attended the University of Maryland School of Medicine, where he won the Jacob Finesinger Award in Psychiatry. He served his residency at Emory University School of Medicine, where he earned the Hope Skobba Memorial Award. He served in the United States Navy as Director of In-Patient Psychiatry at Balboa Naval Hospital. From there, he joined the full-time faculty of UCSD School of Medicine as an Assistant Professor of Psychiatry in charge of emergency services and the medical student clerkship. He briefly served as the Director for all undergraduate education in psychiatry.
"We expect that Dr. Neborsky will have a dual role on our scientific team," said Mr. Warren C. Lau, Chief Executive Officer and President of Nexus BioPharma, Inc. "His background and experience gives him insight into the difficulties of treating the obesity epidemic with the currently available psycho-active drugs that have limited effectiveness at treating the brain's hunger and reward centers. Secondly, his recent work in neurodegeneration will be invaluable as we move forward on recent contributions to the treatment of impaired cognition utilizing our molecular target in the treatment of Alzheimer's Disease."
Dr. Neborsky states, "The potential addition of a Fyn-kinase blocker for the treatment of obesity offers great promise to many psychiatric patients who suffer the unwanted side effects of weight gain and metabolic syndrome (acquired diabetes) from their use of some antidepressants and atypical antipsychotic medications. This side effect currently represents a significant public health hazard and there are no effective treatments except discontinuing the drug. As a member of the scientific advisory committee, I hope to assist Nexus in developing this much needed compound which will hopefully address this need."
About Nexus BioPharma, Inc. www.nexusbiopharma.com
Nexus BioPharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property from research and development activities for treating obesity and type 2 diabetes.
The company is developing a proprietary drug that stimulates the adenosine monophosphate-activated protein kinase (AMPK) pathway, the same key metabolic pathway activated by intense physical exercise. When activated, results include increased metabolism, reduced fat mass, and improved blood chemistry.
The underlying biochemistry is described in an article from the journal Cell Metabolism by Claire C. Bastie, and Jeffrey E. Pessin, entitled, "Fyn-Dependent Regulation of Energy Expenditure and Body Weight Is Mediated by Tyrosine Phosphorylation of LKB1" (Cell Metab. 2010 Feb 3;11(2):113-24).
In completed pre-clinical trials of the pharmaceutical activation of the AMPK pathway, test subjects showed reduced fat mass with no loss of lean muscle mass, plus a higher rate of energy expenditure, increased insulin sensitivity, increased fatty acid oxidation, improved plasma and tissue triglyceride levels, with lower cholesterol. Upon translation of this pharmaceutical activation to humans, these effects are expected to have a significant impact on treating obesity and diabetes.
Cautionary Statement Regarding Forward-Looking Information
This press release may contain certain "forward-looking statements" relating to the business of Nexus BioPharma, and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the impact of the proceeds from the private placement on the Company's short term business and operations,; the general ability of the Company to achieve its commercial objectives, including the ability of the Company to sustain growth; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
Warren C. Lau
[email protected]
(832) 758-7488
SOURCE: Nexus BioPharma, Inc.